Literature DB >> 28095373

Comparison of "Lesion-by-Lesion" and Field Photodynamic Therapy in the Prevention of Actinic Keratoses: A Randomized, Split-Face, Single-Blind Pilot Study.

Inge Seubring1, Joannes M M Groenewoud, Marie-Jeanne P Gerritsen.   

Abstract

BACKGROUND: Actinic keratoses (AKs) are often treated separately, lesion by lesion. However, in the past years, AKs have been described as a field disease and not limited to single clinically apparent lesions. Treatment should therefore target an area of field change which may reduce the risk of development of further AKs, second tumours, and local recurrence.
OBJECTIVE: The primary objective was to determine the number of new lesions at 9 months after methyl aminolevulinate photodynamic therapy (MAL-PDT). Secondary objectives were to determine the number of new lesions at 3 and 6 months after treatment and the percentage reduction of AKs from baseline at 3, 6, and 9 months after MAL-PDT.
METHODS: This was a single-centre, prospective, randomized, split-face, investigator-blinded pilot study with a study duration of 1 year. The study population comprised patients with AKs on the face or scalp, with a maximum of 10 AKs on each side. One side was treated with 1 session of "lesion-by-lesion" MAL-PDT (LT side) and the other side with 1 session of field MAL-PDT (FT side).
RESULTS: At 9 months the FT demonstrated significantly fewer new lesions. At every time point during the follow-up, we found a significant reduction in the number of AKs in the LT as well as in the FT sides. After 3 and 6 months we did not observe significant differences between the sides. However, after 9 months, the LT area showed significantly fewer remaining AKs, whereas the FT area demonstrated significantly fewer new lesions.
CONCLUSIONS: Field treatment results in significantly fewer new AK lesions compared with lesion-by-lesion treatment.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Field photodynamic therapy; In-patient comparison; Lesion-by-lesion photodynamic therapy; Prevention

Mesh:

Substances:

Year:  2017        PMID: 28095373      PMCID: PMC5516406          DOI: 10.1159/000453610

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  18 in total

1.  Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathologic correlation.

Authors:  S T Guenthner; R M Hurwitz; L J Buckel; H R Gray
Journal:  J Am Acad Dermatol       Date:  1999-09       Impact factor: 11.527

2.  Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers.

Authors:  L Bagazgoitia; J Cuevas Santos; A Juarranz; P Jaén
Journal:  Br J Dermatol       Date:  2011-05-26       Impact factor: 9.302

3.  Insight into the number of pre-malignancies and malignancies of the skin in a hospital population in the Netherlands.

Authors:  Margit van Rijsingen; Inge Seubring; Birgitte Maessen-Visch; Sjan Lavrijsen; Bert van Bergen; Johannes Groenewoud; Marie-Jeanne Gerritsen
Journal:  Eur J Dermatol       Date:  2015 May-Jun       Impact factor: 3.328

Review 4.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

Authors:  Boudewijn J M Braakhuis; Maarten P Tabor; J Alain Kummer; C René Leemans; Ruud H Brakenhoff
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

Review 5.  Photodynamic therapy for actinic keratosis in organ transplant patients.

Authors:  N Basset-Seguin; K Baumann Conzett; M J P Gerritsen; H Gonzalez; M Haedersdal; G F L Hofbauer; L Aguado; D Kerob; J T Lear; S Piaserico; C Ulrich
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-12-10       Impact factor: 6.166

6.  Primary prevention of skin dysplasia in renal transplant recipients with photodynamic therapy: a randomized controlled trial.

Authors:  K Togsverd-Bo; S H Omland; H C Wulf; S S Sørensen; M Haedersdal
Journal:  Am J Transplant       Date:  2015-05-27       Impact factor: 8.086

7.  Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy.

Authors:  R M Szeimies; L Torezan; A Niwa; N Valente; P Unger; E Kohl; S Schreml; P Babilas; S Karrer; C Festa-Neto
Journal:  Br J Dermatol       Date:  2012-06-01       Impact factor: 9.302

8.  Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study.

Authors:  Z Apalla; E Sotiriou; E Chovarda; I Lefaki; D Devliotou-Panagiotidou; D Ioannides
Journal:  Br J Dermatol       Date:  2009-10-26       Impact factor: 9.302

Review 9.  The natural history of actinic keratosis: a systematic review.

Authors:  R N Werner; A Sammain; R Erdmann; V Hartmann; E Stockfleth; A Nast
Journal:  Br J Dermatol       Date:  2013-09       Impact factor: 9.302

10.  p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization.

Authors:  S Kanjilal; S S Strom; G L Clayman; R S Weber; A K el-Naggar; V Kapur; K K Cummings; L A Hill; M R Spitz; M L Kripke
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

View more
  1 in total

1.  5-aminolaevulinic acid-based photodynamic therapy inhibits ultraviolet B-induced skin photodamage.

Authors:  Hui Hua; Jia-Wei Cheng; Wen-Bo Bu; Juan Liu; Wei-Wei Ma; Na Ni; Jian Shi; Bing-Rong Zhou; Dan Luo
Journal:  Int J Biol Sci       Date:  2019-08-07       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.